Table 3 Univariate and multivariate analysis using clinicopathological characteristics and LA for overall survival (OS) and recurrence-free survival (RFS) in the discovery cohort.

From: Combination of lymphocyte count and albumin concentration as a new prognostic biomarker for rectal cancer

Variables OS RFS
Univariate Multivariate Univariate Multivariate
n 5-year OS (%) P value HR 95%CI P value 5-year RFS (%) P value HR 95%CI P value
Age
> 65 138 82.5      69.6     
≤ 65 102 93.6  < 0.001* 2.55 1.21–5.74 0.012* 75.7 0.254    
Sex       
Male 163 86.9      72,1     
Female 77 88.3 0.927     73.7 0.948    
Tumor location
Ra 122 86.7      76.9     
Rb-P 118 87.7 0.198     68.5 0.352    
CEA
> 5 99 83.5      66.4     
≤ 5 141 90.0 0.008* 1.75 0.85–3.72 0.125 76.6 0.071 1.13 0.67–1.89 0.638
pT category
pT1/2 75 93.4      87.9     
pT3/4 165 84.7 0.051 1.39 0.58–3.87 0.473 65.5 0.001* 2.30 1.19–4.90 0.011*
pN category
pN− 157 91.2      81.0     
pN+  83 79.3 0.042* 2.06 1.02–4.15 0.042* 55.8  < 0.001* 1.99 1.09–3.01 0.008*
Neoadjuvant therapy
Present 70 90.7      70.8     
Absent 170 85.9 0.465     73.4 0.968    
Histology
Well/mod 223 88.7      74.6     
Por/muc 16 70.7 0.006* 1.81 0.62–4.55 0.257 43.7 0.001* 2.21 1.00–4.08 0.049*
Adjuvant chemotherapy
Present 107 90.5      71.7     
Absent 133 84.7 0.055 1.88 0.92–4.10 0.086 73.5 0.522    
LA
> 5950 120 91.1      80.4     
≤ 5950 120 83.1 0.007* 2.19 1.09–4.58 0.025* 63.8 0.015* 1.61 1.01–2.80 0.048*
  1. CEA carcinoembryonic antigen, well/mod well-differentiated/moderately-differentiated, por/muc poorly-differentiated/mucinous, LA lymphocyte × albumin, HR hazard ratio, CI confidence interval.
  2. * P < 0.05.